This is a sponsored article brought to you by PNY Technologies. In today’s data-driven world, data scientists face mounting ...

Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains ...

LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...

Cadence’s leadership in agentic AI is expanded by integrating portfolio of chip and system design solutions with NVIDIA’s ...

JACKSONVILLE, Fla., March 27, 2026 /PRNewswire/ -- BionicM USA LLC and Brooks Rehabilitation have announced a collaborative clinical research study, titled Adaptive Mobility Technology: A Comparative ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...

At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

Billion-Dollar Opportunity Emerges For RF Sensing Technologies In Offshore Exploration - Financial News Media. Demand surges as operators prioritize safety, uptime, and data-driven operations New York ...

Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NAS ...